Children and adults have shown a strong immune response to a possible Ebola vaccine during clinical trials in Sierra Leone.
The two-dose vaccine from Johnson & Johnson was also found to be safe and well tolerated, according to research published in The Lancet Infectious Diseases.
The EBOVAC-Salone study is the first to test the vaccine in a region affected by the 2014-16 Ebola outbreak, the worst on record.
It is also the first to test the vaccine on children – approximately 20% of cases in that outbreak were in those aged under 15, with children under five being at a higher risk of death.
Some 98% of trial participants showed antibody responses 21 days after the second dose of the vaccine, and the immune response lasted for at least two years in adults.
The two-stage trial was run between September 2015 and July 2018.
The first stage looked at the vaccine’s safety and ability to provoke an immune response, with 43 adults receiving the Ad26.ZEBOV vaccine followed by the…